Iovance BiotherapeuticsIOVA
Market Cap: $3.04B
About: Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Employees: 557
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
58% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 43
41% more repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 80
36% more call options, than puts
Call options by funds: $25.3M | Put options by funds: $18.5M
9% more funds holding
Funds holding: 268 [Q1] → 293 (+25) [Q2]
4.77% more ownership
Funds ownership: 78.32% [Q1] → 83.09% (+4.77%) [Q2]
38% less funds holding in top 10
Funds holding in top 10: 8 [Q1] → 5 (-3) [Q2]
42% less capital invested
Capital invested by funds: $3.24B [Q1] → $1.86B (-$1.37B) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Joseph Pantginis 25% 1-year accuracy 43 / 171 met price target | 220%upside $32 | Buy Reiterated | 12 Aug 2024 |
Piper Sandler Joseph Catanzaro 32% 1-year accuracy 8 / 25 met price target | 0%downside $10 | Neutral Downgraded | 29 Jul 2024 |
HC Wainwright & Co. Joseph Pantginis 25% 1-year accuracy 43 / 171 met price target | 220%upside $32 | Buy Reiterated | 28 Jun 2024 |
JMP Securities Reni Benjamin 41% 1-year accuracy 11 / 27 met price target | 130%upside $23 | Market Outperform Maintained | 20 Jun 2024 |
Financial journalist opinion
Based on 12 articles about IOVA published over the past 30 days